Baselga, 59, is an expert in breast cancer research and played a key role in the development of Herceptin by Genentech, a subsidiary of Roche. He came to Memorial Sloan Kettering in 2013 after serving as chief of hematology and oncology at Massachusetts General Hospital in Boston. Before that, he was a leader at the Vall d’Hebron Institute of Oncology in Barcelona, Spain.
Since September, Dr. Baselga has corrected his conflict-of-interest disclosures in several journals, including two in the New England Journal of Medicine, three in Clinical Cancer Research, five in JAMA Oncology, and two in Cancer Discovery.
In a note that accompanied Dr. Baselga’s correction in the New England Journal of Medicine, editors described his failure as a “breach of trust.”
Dr. Baselga also revised disclosures with the American Society of Clinical Oncology, which said that Dr. Baselga’s participation in future meetings will be contingent on a review of his presentation slides and that his sessions would be monitored for evidence of bias.
The group also said that if Dr. Baselga did not disclose his interactions in the future, he would be barred from participating in any meetings sponsored by A.S.C.O. for two years.
ProPublica and The Times found that Dr. Baselga had failed to report any industry ties in 60 percent of the nearly 180 papers he had published since 2013. That figure increased each year — he did not disclose any relationships in 87 percent of the journal articles that he co-wrote last year.
The A.A.C.R. said its panel of experts will continue to look at conflict-of-interest disclosures, including how to “best harmonize such disclosures and provide greater clarity around these issues.”
Charles Ornstein is a senior editor at ProPublica.
Source : https://www.nytimes.com/2018/12/19/health/baselga-cancer-conflict-disclosure.html